Skip to content
Search

Latest Stories

Kelso Pharma acquires Italian specialty pharma company, Velit Biopharma

Kelso Pharma acquires Italian specialty pharma company, Velit Biopharma

The Velit transaction is an important step for Kelso’s ambition to expand into the rest of Europe

UK-based specialty pharma business, Kelso Pharma has closed the acquisition of Italian specialty pharma company, Velit Biopharma, taking the first step to its European expansion.


The Kelso group of companies, which also includes Glasgow-based Stirling Anglian Pharmaceuticals (SAP), announced its plan to acquire Velit on 13 November 2023.

Velit is specialised in developing “hard to make” medicines, which are made available to patients through partnerships with pharma companies and distributors across Europe, Asia and the Middle East.

Currently, the company has more than 100 partnerships in 48 regions/countries covering 167 products, with more than 15 further launches planned from this year onwards.

Velit’s portfolio features products focused on gastroenterology, dermatology, women’s health, oncology and ophthalmology.

The Velit transaction will further extend Kelso’s therapeutic range, with a number of products available to be commercialised in the UK through its existing infrastructure.

Kelso Pharma CEO, Dr Tom Stratford said: “We welcome the Velit team to Kelso Pharma. I am confident that, together, we can build on this deal as a springboard for our European expansion while continuing to meet the needs of our patients and clinicians.”

Dr Nicola Travierso of Velit, said: “We are delighted to become part of the Kelso Pharma family and look forward to helping Tom and the team grow the business together.”

Established in in 2020, Kelso Pharma focuses on bringing innovative, value added, specialty medicines to the European healthcare markets, with an aim to improve the lives of patients in a cost-effective and ethical manner.

In 2022, Kelso Pharma acquired Glasgow-based SAP, which already has four medicines in the UK healthcare market, including Acepiro (Acetylcysteine) which was launched in early 2023 for treatment of respiratory diseases with viscous mucus.

Kelso completed the acquisition of two UK approved dermatology products from German pharma company, Dermapharm in October last year.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less